Protocol Ledger

NCT06333678 · Phase II · TERMINATED

A Study Comparing Sotorasib With Durvalumab in People With Non-Small Cell Lung Cancer (NSCLC)

Interventional Phase II clinical trial protocol NCT06333678 sponsored by Memorial Sloan Kettering Cancer Center in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-03-20 Enrollment: 10 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06333678
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)10 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06333678
Protocol FieldVerified Registry Value
NCT IdentifierNCT06333678
Consolidated Lead SponsorMemorial Sloan Kettering Cancer Center
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment10 participants (ACTUAL)
Registered Start Date2024-03-20
WhyStopped ClassificationInsufficient / Slow Accrual

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06333678
Hospital Research SiteLocationSite Profile
University of Michigan Rogel Cancer CenterAnn Arbor, MIOpen Hospital Dossier ->
Memorial Sloan Kettering Cancer CenterNew York, NYOpen Hospital Dossier ->
Vanderbilt University Medical CenterNashville, TNOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Memorial Sloan Kettering Cancer Center across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI